Bioventus
BVS
67 hedge funds and large institutions have $109M invested in Bioventus in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 13 closing their positions.
144% more call options, than puts
Call options by funds: $658K | Put options by funds: $270K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
18% more capital invested
Capital invested by funds: $92.6M → $109M (+$16.2M)
2% more funds holding
Funds holding: 66 → 67 (+1)
1.36% more ownership
Funds ownership: 51.2% → 52.55% (+1.4%)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.41M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.05M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$681K |
| 4 |
JIC
Juniper Investment Company
New York
|
+$621K |
| 5 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$474K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.18M |
| 2 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$425K |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$403K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$237K |
| 5 |
E
Ergoteles
New York
|
-$228K |
BVS Hedge Fund Activity: Q3 2023 in Review
67 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q3 2023, worth a combined $109M — up 18% from $92.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new BVS positions and 13 closed out — a net gain of 1 holder — while 26 added to existing stakes and 18 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $1.41M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.18M sold.
- 67 institutional investors held Bioventus (BVS) as of Q3 2023, up from 66 in Q2 2023.
- Funds reported $109M of Bioventus stock for Q3 2023, up 18% quarter-over-quarter.
- 14 funds opened new Bioventus positions in Q3 2023 and 13 closed out, a net change of +1 holder.
- The largest Bioventus buyer in Q3 2023 was Nantahala Capital Management, an estimated $1.41M added.
- The largest Bioventus seller in Q3 2023 was Balyasny Asset Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2023.